Get started
Cullinan Therapeutics, Inc.Cullinan Therapeutics, Inc.Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

CGEM chart


Full chart

CGEM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪476.29 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.14 USD
Net income (FY)
‪−167.38 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪35.47 M‬
Beta (1Y)
0.96

Employees


Employees (FY)
111
Change (1Y)
+26 +30.59%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.51 M‬ USD

About Cullinan Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Nadim Ahmed
Website
cullinantherapeutics.com
Headquarters
Cambridge
Founded
2016
FIGI
BBG00HW2DGQ4
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CGEM news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where CGEM is featured.

See all sparks 


Check out other big names from the same industry as CGEM.

Frequently Asked Questions


The current price of CGEM is 8.14 USD — it hasn't changed in the past 24 hours. Watch Cullinan Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cullinan Therapeutics, Inc. stocks are traded under the ticker CGEM.
CGEM stock has risen by 9.70% compared to the previous week, the month change is a −1.33% fall, over the last year Cullinan Therapeutics, Inc. has showed a −56.00% decrease.
We've gathered analysts' opinions on Cullinan Therapeutics, Inc. future price: according to them, CGEM price has a max estimate of 36.00 USD and a min estimate of 29.00 USD. Watch CGEM chart and read a more detailed Cullinan Therapeutics, Inc. stock forecast: see what analysts think of Cullinan Therapeutics, Inc. and suggest that you do with its stocks.
CGEM reached its all-time high on Mar 10, 2021 with the price of 59.85 USD, and its all-time low was 6.85 USD and was reached on Apr 7, 2025. View more price dynamics on CGEM chart.
See other stocks reaching their highest and lowest prices.
CGEM stock is 3.93% volatile and has beta coefficient of 0.96. Track Cullinan Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cullinan Therapeutics, Inc. there?
Today Cullinan Therapeutics, Inc. has the market capitalization of ‪476.29 M‬, it has increased by 2.33% over the last week.
Yes, you can track Cullinan Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cullinan Therapeutics, Inc. is going to release the next earnings report on May 20, 2025. Keep track of upcoming events with our Earnings Calendar.
CGEM earnings for the last quarter are −0.73 USD per share, whereas the estimation was −0.75 USD resulting in a 2.61% surprise. The estimated earnings for the next quarter are −0.81 USD per share. See more details about Cullinan Therapeutics, Inc. earnings.
Cullinan Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CGEM net income for the last quarter is ‪−47.65 M‬ USD, while the quarter before that showed ‪−40.56 M‬ USD of net income which accounts for −17.47% change. Track more Cullinan Therapeutics, Inc. financial stats to get the full picture.
No, CGEM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 26, 2025, the company has 111 employees. See our rating of the largest employees — is Cullinan Therapeutics, Inc. on this list?
Like other stocks, CGEM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cullinan Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cullinan Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cullinan Therapeutics, Inc. stock shows the sell signal. See more of Cullinan Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.